Table 1. Open in new tab Anthropometric...

Variable

T1D

T2D

Difference (95% CI)

P Value

P_adj Value

Patients, n

Sex

Male

Female

Age, y

45 ± 9

46 ± 10

0.43 (0.0 to 0.86)

0.051

Weight, kg

82 ± 16

−0.91 (−3.29 to 1.46)

0.444

0.416

BMI, kg/m²

27 ± 4

0.01 (−0.12 to 0.13)

0.895

Waist circumference, cm

92 ± 13

94 ± 12

1.74 (−0.20 to 3.69)

0.078

0.086

WHR

0.92 ± 0.08

0.94 ± 0.07

0.02 (0.00 to 0.04)

0.025^a

0.027^a

Diabetes duration, d

182 ± 93

194 ± 102

11.3 (−23.8 to 46.4)

0.522

0.545

Glucose-lowering treatment, n

None

OAD

Insulin

Fasting glucose, mmol/L

7.3 ± 2.5

7.0 ± 1.4

−0.35 (−1.1 to 0.4)

0.331

0.399

HbA1c, mmol/mol

48.9 ± 15.1

46.5 ± 9.0

−2.4 (−6.9 to 2.2)

0.297

0.277

HbA1c, %

6.6 ± 1.4

6.4 ± 0.8

−0.22 (−0.6 to 0.2)

0.297

0.277

TAGs, mmol/L

1.0 (0.7 to 1.5)

1.3 (1.0 to 2.0)

36 (14 to 64)^b

< 0.002^a

HDL, mmol/L

1.5 ± 0.5

1.3 ± 0.4

−0.21 (−0.32 to −0.1)

< 0.001^a

LDL, mmol/L

3.2 ± 0.9

3.5 ± 1.0

0.23 (−0.07 to 0.52)

0.132

0.147

AST, U/L

21.0 (17.6 to 24.7)

21.1 (17.0 to 29.0)

9 (−2 to 21)^b

0.125

0.130

ALT, U/L

22.0 (18.0 to 34.0)

25.5 (18.0 to 40.0)

13 (−3 to 32)^b

0.120

0.137

GGT, U/L

20.5 (14.0 to 30.4)

27.9 (17.0 to 40.0)

27 (4 to 56)^b

0.020^a

hsCRP, mg/dL

0.13 (0.06 to 0.20)

0.17 (0.09 to 0.37)

34 (−4 to 85)^b

0.081

0.080

IL-6, pg/mL

1.3 (0.7 to 2.1)

1.4 (0.9 to 2.0)

19 (−19 to 73)^b

0.371

0.660

Total adiponectin, ng/mL

5178 (3560 to 7929)

4280 (2766 to 5652)

−15 (−28 to 2)^b

0.074

0.007^a

HMW adiponectin, ng/mL

2131 (1292 to 3527)

1815 (935 to 2697)

−4 (−35 to 14)^b

0.279

0.074

HMW/total adiponectin ratio

0.41 (0.35 to 0.50)

0.41 (0.32 to 0.50)

1 (−13 to 16)^b

0.912

0.964

Table 1.

Open in new tab

Anthropometric and Laboratory Characteristics

Variable	T1D	T2D	Difference (95% CI)	P Value	P_adj Value
Patients, n	66	66	NA	NA	NA
Sex			NA	NA	NA
Male	46	46
Female	20	20
Age, y	45 ± 9	46 ± 10	0.43 (0.0 to 0.86)	0.051	NA
Weight, kg	82 ± 16	82 ± 16	−0.91 (−3.29 to 1.46)	0.444	0.416
BMI, kg/m²	27 ± 4	27 ± 4	0.01 (−0.12 to 0.13)	0.895	NA
Waist circumference, cm	92 ± 13	94 ± 12	1.74 (−0.20 to 3.69)	0.078	0.086
WHR	0.92 ± 0.08	0.94 ± 0.07	0.02 (0.00 to 0.04)	0.025^a	0.027^a
Diabetes duration, d	182 ± 93	194 ± 102	11.3 (−23.8 to 46.4)	0.522	0.545
Glucose-lowering treatment, n			NA	NA	NA
None	4	21
OAD	2	39
Insulin	60	6
Fasting glucose, mmol/L	7.3 ± 2.5	7.0 ± 1.4	−0.35 (−1.1 to 0.4)	0.331	0.399
HbA1c, mmol/mol	48.9 ± 15.1	46.5 ± 9.0	−2.4 (−6.9 to 2.2)	0.297	0.277
HbA1c, %	6.6 ± 1.4	6.4 ± 0.8	−0.22 (−0.6 to 0.2)	0.297	0.277
TAGs, mmol/L	1.0 (0.7 to 1.5)	1.3 (1.0 to 2.0)	36 (14 to 64)^b	< 0.002^a	< 0.002^a
HDL, mmol/L	1.5 ± 0.5	1.3 ± 0.4	−0.21 (−0.32 to −0.1)	< 0.001^a	< 0.001^a
LDL, mmol/L	3.2 ± 0.9	3.5 ± 1.0	0.23 (−0.07 to 0.52)	0.132	0.147
AST, U/L	21.0 (17.6 to 24.7)	21.1 (17.0 to 29.0)	9 (−2 to 21)^b	0.125	0.130
ALT, U/L	22.0 (18.0 to 34.0)	25.5 (18.0 to 40.0)	13 (−3 to 32)^b	0.120	0.137
GGT, U/L	20.5 (14.0 to 30.4)	27.9 (17.0 to 40.0)	27 (4 to 56)^b	0.020^a	0.020^a
hsCRP, mg/dL	0.13 (0.06 to 0.20)	0.17 (0.09 to 0.37)	34 (−4 to 85)^b	0.081	0.080
IL-6, pg/mL	1.3 (0.7 to 2.1)	1.4 (0.9 to 2.0)	19 (−19 to 73)^b	0.371	0.660
Total adiponectin, ng/mL	5178 (3560 to 7929)	4280 (2766 to 5652)	−15 (−28 to 2)^b	0.074	0.007^a
HMW adiponectin, ng/mL	2131 (1292 to 3527)	1815 (935 to 2697)	−4 (−35 to 14)^b	0.279	0.074
HMW/total adiponectin ratio	0.41 (0.35 to 0.50)	0.41 (0.32 to 0.50)	1 (−13 to 16)^b	0.912	0.964

Variable	T1D	T2D	Difference (95% CI)	P Value	P_adj Value
Patients, n	66	66	NA	NA	NA
Sex			NA	NA	NA
Male	46	46
Female	20	20
Age, y	45 ± 9	46 ± 10	0.43 (0.0 to 0.86)	0.051	NA
Weight, kg	82 ± 16	82 ± 16	−0.91 (−3.29 to 1.46)	0.444	0.416
BMI, kg/m²	27 ± 4	27 ± 4	0.01 (−0.12 to 0.13)	0.895	NA
Waist circumference, cm	92 ± 13	94 ± 12	1.74 (−0.20 to 3.69)	0.078	0.086
WHR	0.92 ± 0.08	0.94 ± 0.07	0.02 (0.00 to 0.04)	0.025^a	0.027^a
Diabetes duration, d	182 ± 93	194 ± 102	11.3 (−23.8 to 46.4)	0.522	0.545
Glucose-lowering treatment, n			NA	NA	NA
None	4	21
OAD	2	39
Insulin	60	6
Fasting glucose, mmol/L	7.3 ± 2.5	7.0 ± 1.4	−0.35 (−1.1 to 0.4)	0.331	0.399
HbA1c, mmol/mol	48.9 ± 15.1	46.5 ± 9.0	−2.4 (−6.9 to 2.2)	0.297	0.277
HbA1c, %	6.6 ± 1.4	6.4 ± 0.8	−0.22 (−0.6 to 0.2)	0.297	0.277
TAGs, mmol/L	1.0 (0.7 to 1.5)	1.3 (1.0 to 2.0)	36 (14 to 64)^b	< 0.002^a	< 0.002^a
HDL, mmol/L	1.5 ± 0.5	1.3 ± 0.4	−0.21 (−0.32 to −0.1)	< 0.001^a	< 0.001^a
LDL, mmol/L	3.2 ± 0.9	3.5 ± 1.0	0.23 (−0.07 to 0.52)	0.132	0.147
AST, U/L	21.0 (17.6 to 24.7)	21.1 (17.0 to 29.0)	9 (−2 to 21)^b	0.125	0.130
ALT, U/L	22.0 (18.0 to 34.0)	25.5 (18.0 to 40.0)	13 (−3 to 32)^b	0.120	0.137
GGT, U/L	20.5 (14.0 to 30.4)	27.9 (17.0 to 40.0)	27 (4 to 56)^b	0.020^a	0.020^a
hsCRP, mg/dL	0.13 (0.06 to 0.20)	0.17 (0.09 to 0.37)	34 (−4 to 85)^b	0.081	0.080
IL-6, pg/mL	1.3 (0.7 to 2.1)	1.4 (0.9 to 2.0)	19 (−19 to 73)^b	0.371	0.660
Total adiponectin, ng/mL	5178 (3560 to 7929)	4280 (2766 to 5652)	−15 (−28 to 2)^b	0.074	0.007^a
HMW adiponectin, ng/mL	2131 (1292 to 3527)	1815 (935 to 2697)	−4 (−35 to 14)^b	0.279	0.074
HMW/total adiponectin ratio	0.41 (0.35 to 0.50)	0.41 (0.32 to 0.50)	1 (−13 to 16)^b	0.912	0.964

Data presented as mean ± SD or median (25th to 75th percentiles); differences between T2D and T1D presented as mean difference or relative change (%).

Abbreviations: OAD, oral antihyperglycemic drug; P_adj, P value for difference adjusted for matching variables of age, sex, and BMI derived from covariance pattern models.

Statistically significant.

P values and 95% CIs based on two-sided paired two-sample t tests.

This Feature Is Available To Subscribers Only